PDF(Pubmed)
Abstract：
Urticarial vasculitis (UV) is a type of small-vessel vasculitis, which is rarely associated with anti-tumor necrosis factor (TNF)-alpha medication. We describe a 72-year-old woman with multiple comorbidities on several medications, including an adalimumab biosimilar for Hurley stage II recalcitrant hidradenitis suppurativa (HS), who presented with new-onset severe angioedema and a rash with urticarial wheals that covered most of her body surface area. The diagnosis of drug-induced UV is supported by both the history of adalimumab biosimilar use and the histopathology result. The patient responded successfully to a course of doxycycline administered for three months, which was preceded by corticosteroid dosages, both orally and intravenously, to reduce inflammation. The given case highlights the correlation between a distinct dermatologic autoimmune manifestation and TNF-targeted therapy, demonstrating the importance for dermatologists to be aware of the potential side effects of adalimumab biosimilars in order to manage them effectively.
摘要：
荨麻疹性血管炎（UV）是一种小血管血管炎，很少与抗肿瘤坏死因子（TNF）-α药物相关。我们描述了一名72岁的女性，在几种药物上有多种合并症，包括用于HurleyII期顽固性化脓性汗腺炎（HS）的阿达木单抗生物仿制药，她出现了新发的严重血管性水肿和皮疹伴荨麻疹，覆盖了她大部分的体表区域。阿达木单抗生物仿制药使用史和组织病理学结果均支持药物诱导的紫外线的诊断。患者成功接受了为期三个月的强力霉素治疗，之前是皮质类固醇剂量，口服和静脉注射，减少炎症。该病例突出了独特的皮肤病学自身免疫表现与TNF靶向治疗之间的相关性，证明皮肤科医生意识到阿达木单抗生物仿制药潜在副作用的重要性，以便有效管理它们。
